Fexuprazan
Gastroesophageal reflux disease (GERD) and erosive esophagitis
- CAS No.
- 1902954-60-2
- Indication Class
- Gastroenterology / Hepatology
- Patent Expiry
- To be assessed
- Therapeutic Area
- Gastroenterology / Acid-related
- Target / Mechanism
- ATP4A·ATP4B
- Labeled Purity
- 99%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- Confirm per inquiry
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higherNo intermediate entries are on file for this API yet. You can still enquire by CAS number — we will route it to the supply side for manual sourcing.
Listing Logic · Why It's Worth Listing
A next-generation potassium-competitive acid blocker (P-CAB) with faster onset and no food effect versus PPIs, the upgrade direction for acid-related disease.
Gastroenterology / Acid-related · Marketed; available for immediate sourcing
GMP/DMF-ready; supports regulatory filing and audit in target markets
Intermediates confirmed per inquiry
Product Description
Fexuprazan is a promising next-generation gastric acid inhibitor that provides a new treatment option for acid related diseases such as gastroesophageal reflux disease.
Supply source: Unibest · Fexuprazan, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.